Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

@article{GambacortiPasserini2011MulticenterIA,
  title={Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.},
  author={Carlo B Gambacorti-Passerini and Laura Antolini and F. -X. Mahon and François Guilhot and Michael Deininger and Carmen Fava and Arnon Nagler and Chiara Maria Della Casa and Enrica Morra and Elisabetta Abruzzese and Anna D'Emilio and Fabio Stagno and Philipp le Coutre and Rafael Hurtado-Monroy and Valeria Santini and Bruno Martino and Fabrizio Pane and Andrea Piccin and Pilar Giraldo and Sarit Assouline and Muheez Alani Durosinmi and Onno Leeksma and Enrico Maria Pogliani and Miriam Puttini and Eunjung Jang and Josy J Reiffers and Rocco Piazza and Maria Grazia Valsecchi and Dong-wook Kim},
  journal={Journal of the National Cancer Institute},
  year={2011},
  volume={103 7},
  pages={553-61}
}
BACKGROUND Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based on sponsored trials, whereas independent long-term field studies are lacking. PATIENTS AND METHODS Consecutive CML patients who started imatinib treatment before 2005 and who were in complete cytogenetic… CONTINUE READING